## PATENT COOPERATION TREATY

From the

INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: JANE MASSEY LICATA
LAW OFFICES O JANE MASSEY LICATA
66 E. MAIN
STREET MARTON NJ 08053

ref System

NP = 6-23-01

**PCT** 

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing (day/month/year) 0 7 MAR 2001

Applicant's or agent's file reference

RU-0076

IMPORTANT NOTIFICATION

International application No.

International filing date (day/month/year)

Priority Date (day/month/year)

PCT/US99/30751 23 DECEMBER 1999

23 DECEMBER 1998

Applicant

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Commissioner of Patents and Trademarks

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CYNTHIA WILDER

Telephone No. (703) 308-0916

Allens for

Form PCT/IPEA/416 (July 1992) \*

## TENT COOPERATI I TRE.

## From the INTERNATIONAL BUREAU

## **PCT**

## **NOTIFICATION OF ELECTION**

(PCT Rule 61.2)

BRESLAUER, Kenneth, J. et al

To:

Assistant Commissioner for Patents United States Patent and Trademark Office Box PCT Washington, D.C.20231 ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)
29 August 2000 (29.08.00)

International application No.
PCT/US99/30751

International filing date (day/month/year)
23 December 1999 (23.12.99)

Applicant

International filing date (day/month/year)
23 December 1999 (23.12.99)

Applicant

1.	The designated Office is hereby notified of its election made:
	X in the demand filed with the International Preliminary Examining Authority on:
	12 July 2000 (12.07.00)
	in a notice effecting later election filed with the International Bureau on:
2.	The election X was
	was not
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Olivia RANAIVOJAONA

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

## PATENT COOPERATION TREATY

## **PCT**

REC'D 12 MAR 2001

WIPO

RT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference  RU-0076	TOR FURTHER ACTION	xification of Transmittal of International ary Examination Report (Form PCT/IPEA/416)
International application No.	International filing date (day/month/year)	Priority date (day/month/year)
PCT/US99/30751	23 DECEMBER 1999	23 DECEMBER 1998
International Patent Classification (IPC) Please See Supplemental Sheet.	or national classification and IPC	
Applicant RUTGERS, THE STATE UNIVERSI	TY OF NEW JERSEY	
Examining Authority and is  2. This REPORT consists of a  This report is also accom	transmitted to the applicant according total of sheets.  panied by ANNEXES, i.e., sheets of the de-	pared by this International Preliminary to Article 36. escription, claims and/or drawings which have hing rectifications made before this Authority.
(see Rule 70.16 and Sect	tion 607 of the Administrative Instruction	
These annexes consist of a to		
3. This report contains indication		
I X Basis of the repor	rt	
II Priority		
III Non-establishmer	it of report with regard to novelty, inve	entive step or industrial applicability
IV Lack of unity of	invention	
V X Reasoned statemer citations and expla	it under Article 35(2) with regard to nove nations supporting such statement	elty, inventive step or industrial applicability:
VI Certain documents	cited	
VII Certain defects in t	he international application	
VIII Certain observation	s on the international application	
<u></u>		
	<del></del>	<del></del>
Date of submission of the demand	Date of complet	ion of this report
12 JULY 2000	15 FEBRUA	RY 2001 /
Name and mailing address of the IPEA/		er ///// 20
Commissioner of Patents and Tradem Box PCT	CYNTHIA V	WILDER WILL Wins.
Washington, D.C. 20231 Facsimile No. (703) 305-3230	Telephone No.	1 /



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/30751

I. —–	B	isis of t	he report		
1.	With	regard t	o the elements of the inter	national application:*	
	X	-	ernational application a		
	=	the des	scription:		
	[x]		-		, as originally filed
		nages	NONE		filed with the demand
				, filed with the letter of	
		F-6:-	· <u> </u>		
	$\mathbf{x}$	the cla	ims:		
	_	pages			, as originally filed
		pages		, as amended (together with any	
		pages			, filed with the demand
		pages	NONE	, filed with the letter of	
	X	the dra			as originally filed
			NONE NONE	, filed with the letter of	, med with the demand
		pages	NONE	, filed with the letter of	
	$\overline{\mathbf{x}}$	the sec	uence listing part of the	description:	
				. description.	as originally filed
					, filed with the demand
		nages	NONE	, filed with the letter of	
		the lan	guage of publication o	furnished for the purposes of international search f the international application (under Rule 48.3(b) irnished for the purposes of international preliminary ex	).
3.		h regard	i to any nucleotide and	for amino acid sequence disclosed in the internation ed out on the basis of the sequence listing.	al application, the international
		contair	ned in the international	application in printed form.	
		filed to	gether with the interna	ational application in computer readable form	
	Ħ	furnish	ed subsequently to this	Authority in written form	
	ñ	furnish	ed subsequently to this	s Authority in computer readable form.	
	Ħ			ently furnished written sequence listing does not go	beyond the disclosure in the
				on recorded in computer readable form is identical to the	ne writen sequence listing has
.1	$\lceil x \rceil$	The ar	nendments have resulte	ed in the cancellation of:	
→.	ىت	x .	he description, pages	NONE	
		$\square$	he claims. Nos	NONE	
			he drawings, sheets##	e NONE	
5		_	-	(some of) the amendments had not been made, since the	ev have been considered to go
	لــا		•	is indicated in the Supplemental Box (Rule 70.2(c)).**	
*	in'th	acement	sheets which have been fur	mished to the receiving Office in response to an invitation is different annexed to this report since they do not con-	under Article 14 are - referred to tain amendments (Rules 70.16
1			ment sheet containing su	ch amendments must be referred to under item 1 and a	innexed to this report.



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/30751

Novelty (N)	Claims	1-37	YI
· , ,	Claims	NONE	NO
Inventive Step (IS)	Claims	1-37	YI
• * *	Claims	NONE	NO
Industrial Applicability (IA)	Claims	1-37	YI
	Claims	NONE	NO
invention thus supporting the novelty of the invention thus support in the invention that is not support in the invention that is			



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/30751

Supplemental Bo	O X
-----------------	-----

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

## CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): C12Q 1/68; G01N 25/20, 1/18, 31/16, 24/00; C07H 21/02, 21/04 and US Cl.: 435/6, 810; 436/147, 157, 163, 178, 800; 536/23.1

## PATENT COOPERATION TREATY

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY JANE MASSEY LICATA LAW OFFICES O JANE MASSEY LICATA 66 E. MAIN WRITTEN OPINION STREET MARTON NJ 08053 (PCT Rule 66) Date of Mailing (day/month/year) Applicant's or agent's file reference REPLY DUE within TWO months from the above date of mailing RU-0076 International application No. International filing date (day/month/year) Priority date (day/month/year) PCT/US99/30751 **23 DECEMBER 1999 23 DECEMBER 1998** International Patent Classification (IPC) or both national classification and IPC Please See Supplemental Sheet. Applicant RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority 2. This opinion contains indications relating to the following items Basis of the opinion Priority Ш Non-establishment of opinion with regard to novelty, inventive step or industrial applicability Į۷ Lack of unity of invention Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement ٧I Certain documents cited Certain defects in the international application VII VIII Certain observations on the international application 3. The applicant is hereby invited to reply to this opinion. When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension., see Rule 66.2(d). How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9. For an additional opportunity to submit amendments, see Rule 66.4. Also For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis. For an informal communication with the examiner, see Rule 66.6. If no reply is filed, the international preliminary examination report will be established on the basis of this opinion. 4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 23 APRH 2001 Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Washington, D.C. 20231 Telephone No. (703) 308-0916 Facsimile No. (703) 305-3230

Form PCT/IPEA/408 (cover sheet) (July 1998) \*

International application No.

PCT/US99/30751

1. B	isis of the opinion						
1. With regard to the elements of the international application:*							
X   the international application as originally filed							
[x]	pages1-52		as originally filed				
	pages NONE		-				
		, filed with the letter of					
	pages	, thed with the letter of					
X	the claims:						
بن	52.62		, as originally filed				
		, as amended (together with any s					
	pages NONE	· · · · · · · · · · · · · · · · · · ·	_ , filed with the demand				
	pages NONE , file	ed with the letter of					
_							
X	the drawings:						
,							
	pages NONE	, filed with the letter of					
X	the sequence listing part of the description						
		<del></del>					
	pages None	, filed with the letter of					
the The	<ol> <li>With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.         These elements were available or furnished to this Authority in the following language which is:             which is:             the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).             the language of publication of the international application (under Rule 48.3(b)).             the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).         </li> </ol>						
	n regard to any nucleotide and/or amino acid vn on the basis of the sequence listing:	d sequence disclosed in the international appl	ication, the written opinion was				
	contained in the international application	n in printed form.					
	filed together with the international appl	ication in computer readable form					
	-	•					
$\sqcup$	furnished subsequently to this Authority						
	furnished subsequently to this Authority	in computer readable form.					
	The statement that the subsequently furnish international application as filed has been	hed written sequence listing does not go be furnished.	eyond the disclosure in the				
	The statement that the information recorded is been furnished.	in computer readable form is identical to the	writen sequence listing has				
4 X	The amendments have resulted in the ca	encellation of:					
	X the description, pages NONE						
	X the claims, Nos. NONE						
. —	ine drawings, sheets i.g						
5.	This opinion has been drawn as if (some of) beyond the disclosure as filed, as indicated in	the amendments had not been made, since the nthe Supplemental Box (Rule 702(c))	ey have been considered to go				
	scement sheets which have been furnished to the opinion as "originally filed".	e receiving Office in response to an invitation w	nder Article 14 are referred to				

International application No.
PCT/US99/30751

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
l. statement					
Novelty (N)	Claims	1-37	YES		
	Claims	NONE	NO NO		
Inventive Step (IS)	Claims	1-37	YES		
	Claims	NONE	NO NO		
/ Industrial Applicability (IA)	Claims	1-37	YES		
moustrat Applicability (IA)	Claims	NONE	NO NO		
prior art made of record (Olivas et al. Bio stability and inhibition under physiological obtained by electrophoretic mobility shift invention thus supporting the novelty of the NONE  NONE	ionic conditions of assays. The reference inventive steps.	aused by the existence of competing	g equilibria. Results were		
,					
,					
,					
,					

International application No.

PCT/US99/30751

VI	. Certain documents cited			•	
1.	Certain published documents (	Rule 70.10)			
	Application No. Patent No.	Publication (day/month/	Date (year)	Filing Date (day/month/year)	Priority date (valid claim) (day/month/year)
		<del></del>	<del></del>		
	· •			~	•
	,				
	· 1			-	
2	Manager Parks	70.0)			
۷.	Non-written disclosures (Rule		D		Date of written disclosure
٤.	Kind of non-written disclosure		Date of non-wri	tten disclosure th/year)	Date of written disclosure referring to non-written disclosure (day/month/year)
2.			Date of non-wri	tten disclosure th/year)	referring to non-written disclosure
2.			Date of non-wri	tten disclosure th/year)	referring to non-written disclosure
2.	Kind of non-written disclosure		Date of non-wri	tten disclosure th/year)	referring to non-written disclosure
2.	Kind of non-written disclosure		Date of non-wri	tten disclosure th/year)	referring to non-written disclosure
2.	Kind of non-written disclosure		Date of non-wri	tten disclosure th/year)	referring to non-written disclosure
2.	Kind of non-written disclosure		Date of non-wri	tten disclosure	referring to non-written disclosure
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)
	Kind of non-written disclosure		(day/mon	th/year)	referring to non-written disclosure (day/month/year)

International application No.

PCT/US99/30751

Sup	D	le	m	en	ta	lΒ	o x
-----	---	----	---	----	----	----	-----

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

#### TIME LIMIT:

The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.

#### CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): C12Q 1/68; G01N 25/20, 1/18, 31/16, 24/00; C07H 21/02, 21/04 and US C1.: 435/6, 810; 436/147, 157, 163, 178, 800; 536/23.1



## INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/30751

i .	SSIFICATION OF SUBJECT MATTER						
IPC(7) :C12Q 1/68; G01N 25/20, 1/18, 31/16, 24/00; C07H 21/02, 21/04 US CL : 435/6, 810; 436/147, 157, 163, 178, 800; 536/23.1							
According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIEL	B. FIELDS SEARCHED						
Minimum d	ocumentation searched (classification system follower	d by classification symbols)	<del> </del>				
U.S. :	435/6, 810; 436/147, 157, 163, 178, 800; 536/23.	1					
Documental	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
	Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.						
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		• • • • • • • • • • • • • • • • • • • •				
Category*	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.				
A,P	HOLBROOK et al. Enthalpy and formation of an oligomeric DNA Duple coupled processes of formation and A Helices. Biochemistry 19 August 1999 especially pages 8410 "Analysis and Dilines 1-43. See also abstract.	Association of single-stranded 9, Vol. 38, pages 8409-8422,	1-16				
A,P	GELFAND et al. A quantitative stabilities of nucleic acid. Proc. Natl. 1999, Vol. 96, pages 6113-6118. See		1-37				
X Furth	ner documents are listed in the continuation of Box C	See patent family annex.					
i '	ecial categories of cited documents:	"T" later document published after the inte date and not in conflict with the appli the principle or theory underlying the	cation but cited to understand				
"E" ear	be of particular relevance  the document published on or after the international filing date  cument which may throw doubts on priority claim(s) or which is	*X* document of particular relevance; the considered novel or cannot be consider when the document is taken alone	claimed invention cannot be				
*O" do	ed to establish the publication date of another citation or other social reason (as specified)  cument referring to an oral disclosure, use, exhibition or other	"Y" document of particular relevance; the considered to involve an inventive combined with one or more other such	step when the document is				
*P* do	name  cument published prior to the international filing date but later than  priority date claimed	being obvious to a person skilled in the "&" document member of the same patent					
Date of the	actual completion of the international search	Date of mailing of the international sea	irch report				
09 MARC	CH 2000	0 6 APR 2000					
Commissio Box PCT	nailing address of the ISA/US ner of Patents and Trademarks n, D.C. 20231	Authorized officer  Cynthia Wilder	Ollin Jon				
Facsimile N		Telephone No. (703) 308-0916	/)				
Form PCT/I	Form PCT/ISA/210 (second sheet) (July 1998) *						







International application No. PCT/US99/30751

	·		
C (Continuat	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	<del></del>	
Category*	Citation of document, with indication, where appropriate, of the relev	ant passages	Relevant to claim No
A	OLIVAS et al. Competitive triplex/quadruplex equilibinvolving guanine-rich oligonucleotides. Biochemistry. 1995, Vol. 34, pages 278-284. See abstract.	oria 24 January	1-16
A,P	US 5,972,612 A (MALMQVIST ET AL) 26 October 1 (26/10/99), column 4, lines 19-24, column 5, lines 30-3 64, column 6, lines 30-49.	1999 3 and 46-	1-16, 28, 29, 37



## INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/30751

#### **B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

## WEST 1.2, MEDLINE, BIOSIS, SCISEARCH, EMBASE

search terms: nucleic acid, duplex, stability, equilibria, competitive, solution, tritation, screening, concentration, temperature, label, FET label, relative change, surface plasmon, resonnance spectroscopy, solid support, abasic site, synthetic, modified, wavelength, donor and acceptorm fluorescent, SNP or single nucleotide polymorphism, curve, eximer fluorescence, enthalpy, amount, binding same compete, disrupt or break, heating or denaturing, enthalpy same data

## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12Q 1/68		(11) International Publication Number: WO 97/04129
		(43) International Publication Date: 6 February 1997 (06.02.97)
(21) International Application Number: PCT/SE (22) International Filing Date: 12 July 1996 (		DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data: 9502608-4 14 July 1995 (14.07.95)		Published With international search report. SE
(71) Applicant (for all designated States except US): PHAF BIOSENSOR AB [SE/SE]; S-751 82 Uppsala (SE		IA
(72) Inventors; and (75) Inventors/Applicants (for US only): MALMQVIST, [SE/SE]; Rörbäcksvägen 39, S-757 57 Uppsala (SE SON, Björn [SE/SE]; Flogstavägen 126, S-752 63 (SE).	). PER	S-
(74) Agents: WIDÉN, Björn et al.; Pharmacia AB, Patent 751 82 Uppsala (SE).	Dept.,	S-
(64) Testa METHOD FOR MICHELO ACTO SEQUENCE	DIC.	

## (54) Title: METHOD FOR NUCLEIC ACID SEQUENCING

#### (57) Abstract

A method of analysing nucleic acid sequences comprises measuring by surface sensitive detection technique the binding interaction between a first nucleic acid sequence and a second nucleic acid sequence, one of the first and second nucleic acid sequences being immobilized to a solid phase surface, to determine the affinity or an affinity related parameter for the binding reaction as indicative of the extent of complementary between the first and second nucleic acid sequences. The method is characterized in that the measurement of the binding interaction is performed at annealing conditions adjusted such that the dissociation rate constant for the binding interaction corresponding to full complementarity between the first and second nucleic acid sequences is greater than about  $10^{-3}$  per second, thereby permitting equilibrium for the interaction to be rapidly attained.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
ΑU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
₿G	Bulgaria	IT	kaly	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sedan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	u	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

10

15

20

30

35

## METHOD FOR NUCLEIC ACID SEQUENCING

## FIELD OF THE INVENTION

The present invention relates to an improved method of nucleic acid sequencing based on the detection and measurement of hybridization interactions.

## BACKGROUND OF THE INVENTION

The generation of DNA sequence information has dramatically increased due to the large programs for sequencing of the human genome. Today that work is mainly done by traditional gel electrophoretic separation of DNA fragments terminated at different positions, either enzymatically (dideoxy chain termination method according to Sanger et al., Proc. Natl. Acad. Sci. USA 74: 5463-5467 (1977)) or chemically (chemical degradation method according to Maxam and Gilbert, Proc. Natl. Acad. Sci. USA 74: 560-564). These systems are, however, both time- and labour-intensive.

There is therefore a general need for more effective methods for de novo sequencing of DNA as well as for repeated sequencing of known sequences for analysis of mutations, such as point mutations. The mutation analysis will increase as more information will be gathered about and also due to the need to veri mutations in biotechnology work.

Sequencing by hybridian the correlation between different diseases and mutations and also due to the need to verify deliberately introduced

Sequencing by hybridization (SBH) (see e.g. Drmanac et al., Genomics 4: 114; Strazoski et al., Proc. Natl. Acad. Sci. USA 88: 10089 (1991); Bains and Smith, J. Theoretical Biol. 135: 303 (1988); and US-A-5,202,231) has become an interesting alternative to traditional sequencing with a potential for higher through-put of information. This type of system utilizes the information obtained from multiple hybridizations of the polynucleotide of interest, using short oligonucleotides to determine the nucleic acid sequence. However, there are several technical problems associated with this technology. For example, while today there are ways to build arrays of oligonucleotides on a

15

20

25

30

35

chip based on the synthesis of oligoprobes and photolitographic techniques, it is still complicated to provide on a chip the large set of oligonucleotide probes required for determining a random nucleic acid sequence. Further, the detection of interaction of labelled target DNA is normally done by fluorescent or radioactivity measurements. Such detection is dependent on washing of the chip to get rid of residual labelled target molecules and the oligoprobes must therefore bind rather strongly to the target molecules. There are also problems with the binding of oligoprobes with a single base mismatch in combination with the different sensitivity to washing conditions dependent on base pair composition, G:C being more stable than A:T. One attempt to overcome such problems is to use

tetraalkylammonium salts that eliminate the difference in

stability of G:C and A:T base pairs.

Even if differences in base composition can be compensated for, the whole SBH procedure is based on interaction, washing, and detection of hybridized target-DNA and oligoprobe. The conditions for the hybridization thus have to be adjusted for a stable hybridization which can be detected only after several washing cycles. Dependent on the position of the mismatch of single bases, base composition, oligoprobe length and temperature, there will be several hybridizations of oligomers that will show up as weaker binding and such interactions will be problematic to determine. Temperature and salt gradients elution have been suggested but are difficult to elaborate technically.

Due to the conditions needed for hybridization there is also always a potential risk for the target DNA to hybridize to itself due to complementary regions of the DNA.

A major disadvantage of SBH is, however, that the information is exclusively based on short-range information and the fact that overlaps are unique. Success is dependent on whether or not there are repeated sequences in the nucleic acid to be analysed. The need and importance of

10

15

20

25

30

35

repeated sequences are known from several situations, not least in the analysis of genes like, for example, the gene for Huntington's disease where repeated sequences and the amount of repeats have clinical relevance.

For the analysis of known sequences or of a particular site, mutation analysis may be advantageous. An example of this is the mutation dependent tumour frequency found for proteins such as p53. Binding of p53 to DNA is crucial for a correct control of cell growth and mutation dependent methods for therapy are likely to be developed. Furthermore, the kind of mutation detected may affect the treatment and aid in selecting the appropriate drug.

Label-free real-time measuring techniques, such as those based on surface plasmon resonance (SPR), have been used to study the hybridization of DNA and oligomeric probes (oligoprobes). Attempts have also been made to analyse the kinetic information of the hybridization to determine the degree of hybridization, e.g. to detect mutant sequences, as described in Biosensor Application Note 306, 1994, Pharmacia Biosensor AB, Sweden. It has, however, been found that such analyses are difficult to use for obtaining relevant mismatch information as the kinetics for hybridization is complex under the conditions for hybridization normally used, which result in the formation of relatively stable hybridization complexes with long half-lives.

WO 93/25909 discloses the use of label-free techniques mentioned above in combination with immobilised receptors, specifically antibodies, which are selected or designed to have a high dissociation constant, or "off-rate", for the binding of analyte to the receptor. Such a detection system will rapidly respond to changes in the analyte concentration and regeneration of the sensing surface supporting the receptor will not be required. Typically, the receptor is selected such that the dissociation rate constant ( $k_{\rm off}$  or  $k_{\rm diss}$ ) for a particular analyte of interest is higher than  $10^{-2}$  per second.

PCT/SE96/00949

WO 97/04129

5

10

15

20

25

30

35

WO 95/00665 discloses a method of providing the sequence of a single stranded nucleic acid molecule, which when hybridized to a complementary single stranded molecule results in a double (duplex) structure having a preselected value for a free energy parameter, such as ligand binding, melting temperature or affinity for a target sequence. Thereby nucleic acid molecules may be produced which are tailored for specific applications, e.g. nucleic acid molecules with a defined affinity for a ligand which binds to the DNA and regulates the expression of a protein encoded by the nucleic acid.

## SUMMARY OF THE INVENTION

One object of the present invention is to provide a nucleic acid sequencing method based on hybridization interactions at a solid phase surface, which method is more rapid to perform than the prior art methods and which may not require regeneration of the surface between measurements.

Another object of the invention is to provide a sequencing method which is more sensitive than the prior art methods to obtain mismatch information, i.e. in determining whether there is full complementarity between hybridizing nucleic acid fragments or not.

Still another object of the invention is to provide a sequencing method which permits the use of short oligonucleotide probes.

Another object of the invention is to provide a sequencing method which permits the detection of repeated sequences.

Yet another object of the invention is to provide a sequencing method which is less susceptible to the presence of complementary regions in a target nucleic acid sequence.

It has now according to the present invention been found that the above and other objects and advantages may be attained by providing for reaction conditions which, on one hand, give lower affinity but, on the other hand, permit rapid association and dissociation in the hybridization interactions at the surface. More

10

15

20

25

30

35

particularly, the reaction conditions should be selected such as to obtain a high dissociation rate constant for the hybridization event.

In contrast to the above-mentioned WO 93/25909 which describes a high dissociation rate obtained by selection or design of molecular properties of the receptor, the present invention provides for the desired high dissociation rate by appropriate adjustment of the reaction conditions.

The present invention thus relates to a method of analysing nucleic acid sequences, which method comprises measuring by surface sensitive detection technique the binding interaction between a first nucleic acid sequence and a second nucleic acid sequence, one of the first and second nucleic acid sequences being immobilized to a solid phase surface, to determine the affinity or an affinity related parameter for the binding reaction as indicative of the extent of complementarity between the first and second nucleic acid sequences. The invention is characterized in that the measurement of the binding interaction is performed at annealing conditions adjusted such that the dissociation rate constant for the binding interaction corresponding to full complementarity between the first and second nucleic acid sequences is greater than about 10-3 per second, thereby permitting equilibrium for the interaction to be rapidly attained.

The term nucleic acid is to be interpreted broadly and in addition to DNA and RNA also includes nucleic acid analogues, such as modified DNA or RNA, or other hybridizing nucleic acid like molecules, such as PNA (peptide nucleic acid).

The term annealing as used herein refers to the combination and interactions of two complementary nucleic acids.

The first and second nucleic acids may each be singleor double-stranded, or single-stranded DNA or RNA complexed with a different molecule, such as a modified nucleic acid, PNA, a peptide, etc.

10

15

20

25

30

35

In a preferred embodiment, the dissociation rate constant is higher than about  $10^{-2}$  per second, especially higher than about  $10^{-1}$  per second.

Other preferred embodiments of the invention are described below.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention thus relates to the analysis of the interaction between a first nucleic acid and a complementary second nucleic acid under annealing conditions where high kinetic (dissociation rate) constants are present in the interaction and equilibrium of the reaction therefore can be achieved rapidly, i.e. that the reaction will readily reach equilibrium within a reasonable time during the experiment. This is valid for the formation of e.g. DNA-DNA dimers as well as sequence dependent formation of other complexes of nucleic acids.

The necessary conditions for the desired high dissociation rate may be obtained by proper selection of one or more of (i) the solvent, ionic strength and/or pH, (ii) the reaction temperature and (iii) the nucleic acid probe length. In the second case (ii), which is presently preferred, a reaction temperature is selected which is closer to the melting temperature, Tm, in the annealing of complementary DNA fragments than used in conventional hybridization assays for the particular chemical environment or above the melting temperature ("Tm" being the temperature at which half of the hybridization is lost at equilibrium). The annealing of the nucleic acids reflects the response obtained for a particular affinity at the conditions used and the relative affinity can be determined with high precision.

Thus, for a certain interaction, the dissociation rate constant  $(k_{\mbox{diss}})$  is dependent on the reaction temperature or the reaction medium. While the equilibrium response level may be controlled by selection of nucleic acid concentration, the reaction kinetics will be dependent on the temperature and the reaction medium.

15

20

25

30

35

The method of the invention may be performed by analysing the interaction of either (i) the target nucleic acid, such as a target DNA, over different oligomeric probes, such as oligoDNA probes, immobilized on the solid phase surface, or in other words, sensing surface, or (ii) a series of oligomeric probes over a surface having a target nucleic acid immobilized thereon.

It is readily understood that under standardized conditions with known solution concentrations, a single determination for each oligoprobe and target molecule, respectively, may be sufficient for a comparison to a standard value. As is per se known in the art, by using a concentration close to the inverse of the affinity constant, the sensitivity to changes in affinity will be at its maximum.

There are several advantages of working at annealing conditions closer to the melting temperature than that conventionally used for hybridization or above that, as will be explained below.

With reference first to method aspect (i) above with oligoprobes immobilized on the sensing surface, this variant may be performed sequentially with a different single oligoprobe immobilized on the sensing surface or with an array of different oligoprobes immobilized.

With dissociation rate constants higher than about  $10^{-3}$  s<sup>-1</sup> the equilibrium will be reached rapidly, and there may be no need for regeneration of the oligoprobesupporting sensing surface as the complex formed at the surface will dissociate within a few minutes spontaneously. The affinity can thus rapidly be determined and a new sample of target nucleic acid can be analysed without regeneration of the sensing surface.

By using a series of oligoprobes, each representing a part of a known sequence, mutations in the target DNA can be analysed as a decrease in affinity for the particular oligoprobe interaction with the target nucleic acid, and the position for the mutation may also be identified, as will be described in more detail below. If all possible

15

20

25

30

35

combinations of oligoprobes can be analysed, it is readily understood that not only the position for a mutation can be determined but also the base change in question.

Measurements of affinity of the interaction under such annealing conditions that provide for a high dissociation rate constant will also reduce problems associated with target nucleic acid intramolecular complementary structures, as the latter will have a lower tendency to be formed under rapid kinetic conditions and be under exchange with the immobilized oligomeric nucleic acid on the surface.

Another problem usually experienced in sequencing by hybridization (SBH) is to obtain a good nucleic acid preparation and to know the concentration of the amount of active nucleic acid, the term "active" referring to the hybridization capability. Under conditions of continuous flow and a diffusion rate limited association, the initial association of target DNA to an immobilized oligoprobe will be concentration dependent and can be used for concentration determination of the active target DNA. Such a concentration determination will be required for correlating the affinity measurements to literature data.

The well-known prior art problem in sequencing by hybridization related to the presence of repeated sequences can also be overcome by the present procedure of affinity measurements under annealing conditions with high dissociation rate constants. Since a repeated sequence can interact with different oligoprobes immobilized on the sensing surface, the avidity effects of such multiple interactions will give rise to a higher "apparent" affinity than expected and a much smaller "apparent" dissociation rate constant. The affinity determinations will thus be sensitive for repeated sequences as an increase in apparent affinity, whereas a decrease in affinity will be correlated to a mismatch.

The above described first method aspect of the invention, where an oligoprobe is immobilized on the sensing surface and a larger nucleic acid fragment to be

10

15

20

25

30

35

sequence analysed is present in solution, is suitable for large arrays of oligoprobes and a detection system that can analyse a large amount of interaction at the same time. However, the reversed analytical situation according to the above-mentioned second method aspect relating to the sequential analysis of oligoprobe interactions with immobilized target nucleic acid is also useful.

Under such conditions, for example, the amount of repeated sequences can be correlated to the amount of bound oligoprobes as long as they react independently of each other. In this way repeated sequences can be quantified and will not be dependent on avidity effects as mentioned above.

The increase in binding due to several binding positions on the immobilized target nucleic acid can therefore be described with the same dissociation rate constant as the single interaction, in contrast to the case of a multiple interaction with target nucleic acid in solution where the interactions with several different oligoprobes immobilized on the surface will give rise to an increased signal coupled to a lower dissociation rate constant.

Since in the present invention, association rate is used to measure the concentration of the analyte, the equilibrium response level will be a measure of affinity, a complete match of hybridizing sequences having a higher afffinity than a mismatch. A higher equilibrium level with the same dissociation rate constant will therefore be a measure of the amount of repeated sequences, whereas an increase in signal in combination with a smaller "apparent" dissociation rate constant will be a measure of multiple interaction for that sequence. Information from the dissociation part of the interaction can thus be used in combination with the affinity measurement for verification of the interaction and to make the method as sensitive as possible for detecting a mismatch.

To identify positions for a mutation in a nucleic acid fragment, such as a DNA fragment, it may be advantageous to

10

15

20

25

30

35

use a scanning approach. If the mutation position is unknown, an exemplary procedure may be as follows:

The DNA fragment is immobilized on the sensing surface.

The position for the mutation is then scanned by sequentially contacting the surface with solutions of oligoprobes, each covering a respective part of the whole DNA target molecule.

The part or parts of the DNA target which are found to contain a mutation are then subjected to a detailed analysis of the position of the mutation by overlapping probe analysis in a "minisequencing" format.

The identity of the base mutation may then be determined by testing the four base variants (A, C, T and G) of an oligoprobe with respect to the mutated position. If desired, this last step can be done directly in the above minisequencing format if all possible combinations of oligoprobes are tested.

The above described procedure may be beneficial as sequencing analyses often will be done with samples which do not contain any mutations therein and it is understood that the described scanning approach can be a very rapid procedure.

A corresponding scanning procedure may, of course, be performed in the reversed mode with the oligoprobes immobilized on the surface and the target nucleic acid in solution.

The surface sensitive detection used in the method of the invention may be obtained by various detection systems. In a suitable type of detection system, a change in a property of the sensing structure is measured as being indicative of binding interaction at the sensing surface. Among these methods are, for example, mass detecting methods, such as piezoelectric, optical, thermo-optical and surface acoustic wave (SAW) methods, and electrochemical methods, such as potentiometric, conductometric, amperometric and capacitance methods. It is also possible to use short range radioactivity, such as scintillation

10

15

35

plastics in close proximity to the interaction position of <sup>3</sup>H or other short range ionising radiation.

Among optical methods may particularly be mentioned those that detect surface refractive index, such as reflection-optical methods, including both internal and external reflection methods, e.g. ellipsometry and evanescent wave spectroscopy (EWS), the latter including surface plasmon resonance spectroscopy (SPRS), Brewster angle refractometry, critical angle refractometry, frustrated total reflection (FTR), evanescent wave ellipsometry, scattered total internal reflection (STIR), optical wave guide sensors, evanescent wave based imaging, such as critical angle resolved imaging, Brewster angle resolved imaging, SPR angle resolved imaging, etc., as well as methods based on evanescent fluorescence (TIRF) and phosphorescence.

Among the optical methods mentioned above, especially SPRS has attracted much attention recently. The phenomenon of SPR is well known. In brief, SPR is observed as a dip in intensity of light reflected at a specific angle from the 20 interface between an optically transparent material, e.g. glass, and a thin metal film, usually silver or gold, and depends on among other factors the refractive index of the medium (e.g. a sample solution) close to the metal surface. A change of refractive index at the metal surface, such as 25 by the adsorption or binding of material thereto, will cause a corresponding shift in the angle at which SPR occurs. To couple the light to the interface such that SPR arises, two alternative arrangements may be used, either a metallized diffraction grating (Wood's effect), or a 30 metallized glass prism or a prism in optical contact with a metallized glass substrate (Kretschmann effect). For further details on SPR, reference is made to our WO 90/05295.

The measurements in the present invention are preferably performed in a flow system type biosensor, permitting rapid kinetics to be identified. An example of

30

35

such a biosensor system is the BIAcore® system (marketed by Pharmacia Biosensor AB, Uppsala, Sweden).

The present invention will now be illustrated by the following non-limiting Examples, reference also being made to the accompanying drawings.

## BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is an overlay plot of sensorgrams (response vs time) for the hybridization of matching as well as mismatching 7- and 8-mers (NIPE32-36) to an immobilized target DNA sequence (BP22).

Fig. 2 is a plot of binding curves (equilibrium responses vs concentration) for different concentrations of the oligoprobes in the hybridization in Fig. 1.

Fig. 3 is a plot of binding curves for a number of oligoprobes (BP35, 47-56) to an immobilized p53 derived wild-type (wt) target DNA sequence (BP44).

Fig. 4 is another type of plot of the binding curves in Fig. 3.

Fig. 5 is a corresponding plot to that in Fig. 4
20 showing the binding of the same oligomers (BP35, 47-56) to
a mutant target DNA sequence (BP45).

Fig. 6 is a corresponding plot to that in Fig. 5 showing the binding of the same oligomers (BP35, 47-56) to another mutant target DNA sequence (BP46).

25 Fig. 7 is a resume of the binding curves in Figs. 4 to 6.

Fig. 8 is an overlay plot of sensorgrams for the binding of a wt target DNA (BP68) to a set of immobilized oligoprobes (BP63, 64 and 66).

Fig. 9 is an overlay plot of sensorgrams for the binding of a mutant target DNA (BP69) to a set of immobilized oligoprobes (BP63, 64 and 66).

Fig. 10 is an overlay sensorgram showing the sequential hybridization of a series of oligoprobes (BP47-51, BP35, BP52-56) to a target wild-type (wt) DNA (BP44) and mutant DNA (BP45) in series.

10

15

30

35

Fig. 11 is a diagram showing a subtraction of the two sensorgrams for the wt and mutant target DNA in Fig. 10 from each other.

Fig. 12 is a plot of binding curves (equilibrium response vs concentration) for the hybridization of an oligoprobe (BP61) to an immobilized target DNA (BP46) at different temperatures.

#### EXAMPLES

The experimental work described below is essentially based on the hybridisation of oligonucleotide probes having matching 8-mer sequences. The target oligonucleotide was in no case exceeding the size of a 50-mer. A set of reagents with oligosequences derived from exon 6 of the p53 gene was used. Hybridisations were performed in two formats, either straight, i.e. the probe (the 8-mer) in solution and the target DNA on the surface, or reversed, with the probe on the surface and the target in solution.

## Materials and Methods

The analytical instrument used for the analyses was
20 either a BIAcore® or a BIAcore® 2000 system (Pharmacia
Biosensor AB, Uppsala, Sweden), which are biosensor systems
based on SPR and having four flow channels. As sensing
surface was used Sensor Chip CM5 or SA5, both with
instrument immobilised streptavidin (SA), or Dx500 or Dx40
25 matrices with batch immobilised SA.

Generally, a buffer consisting of 10 mM Hepes, 0.5 M NaCl, 3.4 mM EDTA, 0.002% Surfactant P20, pH 7.4 was used for hybridisation. The same buffer was used for capturing of biotinylated ligands. The ligand concentration used for capturing was ~1 μg/ml. Variable contact times were used to control ligand surface concentrations. Oligonucleotides, denoted "BP" or "NIPE", were purchased from Pharmacia Biotech AB, Uppsala, Sweden (BP1-69), Scandinavian Gene Synthesis, Köping, Sweden (NIPE8, 19-22) or KEBO Lab, Stockholm, Sweden (NIPE32-36).

When necessary, HCl, pH 2.15, was used for the regeneration of the surface between each hybridisation cycle. The hybridisation temperature was 25 °C. The

equilibrium response ("Req") was obtained by taking the report point at steady-state in an active flow cell, subtracted by the corresponding value in a flow cell without captured oligonucleotide. The Req-response for each probe concentration was exported to the BIAeval<sup>™</sup> software (Pharmacia Biosensor AB) and the affinity was determined by a non-linear procedure. A contact time of three minutes and a flow rate of 15 μl/min was used for a typical cycle of analysis. The hybridisation studies were performed either (i) with a biotinylated target on the surface and 8-mer probes in solution or (ii) with biotinylated probe on the surface and the target molecule in solution. These procedures are referred to as "straight" and "reversed" mode, respectively.

15 EXAMPLE 1

## Hybridization of different oligoprobes to immobilized target DNA under equilibrium conditions

The following oligonucleotides were tested:

NIPE32: 3' CGTAGAAT (fully matched)

20 NIPE33: 3 G-----

25

35

NIPE34: 3' \_----

NIPE35: 3' -----G

NIPE36: 3' -----

"-" indicates the same base as the fully matched sequence, and " " indicates no base.

The following target DNA sequence was used:

BP22: 5' Bio TTTTTTTTGCATCTTATTTTTTT, where "Bio" indicates a biotin label.

Hereinafter, "RU" refers to resonance units, and "Fc1" 30 refers to flow channel 1, etc.

BP22 was captured (1523 RU) in Fc1 on a SA5 chip and 0.4  $\mu$ M probe was hybridised. The results are shown in Fig. 1. As appears from the Figure, the 3'-end mismatch does not bind, while the 5'- dito binds, but not as strongly as the matched 8-mer. Of the 7-mers, NIPE36 binds, but not NIPE34, which might reflect the different GC-contents, 3/7 and 2/7, respectively.  $R_{eq}$  -responses were taken as the flow cell difference Fc1 - Fc2.

30

BP22 was then captured on SA5 at different surface concentrations: Fc1, 2, 3 & 4 with 296, 808, 1314 and 0 RU, respectively. Then, NIPE 32-36 were passed serially over the chip at concentrations of 15 nM - 32  $\mu$ M. In Fig 2, all probes (NIPE32-36) are compared with Reg-responses plotted 5 vs. concentration. As can be seen in the Figure, NIPE32, 35 and 36 reach Rmax at a high concentration and it is possible to determine the affinities. The equilibrium dissociation constant ( $K_D$ ) was 0.85, 1.5 and 1.5  $\mu M$ , respectively. The 3'-end mismatch (NIPE33) and the 7-mer 10 (NIPE34) had much lower affinities. As seen from the Figure, the R<sub>max</sub> value for NIPE35 is ~15% lower than for NIPE32. This is probably an effect of loss of ligand or sub-optimal regeneration with each cycle. The baseline drift was on average 0.7 RU/cycle over 100 cycles and the 15 probes were run in order starting with NIPE32 and ending with NIPE36. With 1300 RU of a 24-mer ligand, 430 RU of an 8-mer probe would be expected to bind. At Rmax, 380 RU were bound, e.g. a near 90% occupancy. When NIPE35 comes in, after 60 cycles, ligand concentration may be decreased, but 20 also, some previously hybridised probe may have got stuck on the target, thus decreasing the active surface concentration. The lower response of NIPE36 is probably an effect of the lower molecular weight.

A second set of probes was then constructed with 8-mer oligonucleotides, covering the whole target molecule with one base shift per probe. Three biotinylated target molecules based on the p53 system were also constructed, one "wild-type" to which all probes were fully matched and two targets with either a substitution of C for T or T for A.

30

35

	5'-B-tttCCTCAGCATCTTATCCGAGttt	BP44	"wt"
	5'-B-tttCCTCAGCATTTTATCCGAGttt	BP45	"mutC>T"
	5'-B-tttCCTCAGCAACTTATCCGAGttt	BP46	"mutT>A"
5	GGAGTCGT	BP47	
	GAGTCGTA	BP48	
	AGTCGTAG	BP49	
	GTCGTAGA	BP50	
	TCGTAGAA	BP51	
10	CGTAGAAT	BP35	
	GTAGAATA	BP52	
	TAGAATAG	BP53	
	AGAATAGG	BP54	
	GAATAGGC	BP55	
15	AATAGGCT	BP56	
	TCGTAGAT	BP57	
	ACGTAGAA	BP58	
	GAATAGGG	BP59	
	CAATAGGC	BP60	
20	CGTTGAAT	BP61	
	CGTAAAAT	BP62	

BP57 and 58 have A or T in either end and should be compared with BP51. Correspondingly, BP59 and BP60 have a G or C in either end and should be compared with BP55. BP61 and 62 are fully matched to the "mutants" BP46 and BP45, respectively.

In the first experiment, the binding of probes BP35 and BP47-56 to the target BP44 was tested. The concentration range was 31 nM - 64  $\mu$ M and the binding curves obtained are presented in Fig. 3. A striking observation is that the range of affinity is quite wide for these 8-mer probes spanning from 2 x  $10^5$  - 6 x  $10^6$  M<sup>-1</sup>. A fairly good correlation between the affinities obtained and Tm-values calculated as 2 x n(A+T) + 4 x n(G+C) was found. Fig. 4 shows the binding curves of the probes on the "wt"-target. By comparing this figure to Fig. 5, which shows corresponding binding curves on a mutant target (BP45), where C was changed to T, the effect of single base pair

mismatch is clearly demonstrated. The position of the mismatch has a dramatic effect on binding. The same effect is seen in Fig. 6 with target BP46, where T was changed to A. Fig. 7 is a resume of Figs. 4-6, showing only the Reqresponses of the highest concentrations of each probe. The "U-shaped profiles" of the mutant targets differ clearly from the profile of the wt-target, suggesting that it is possible to discriminate perfectly matched probes from end-mismatched ones. Comparing the highest response for each probe was found to be discriminative.

#### EXAMPLE 2

# Hybridization of different target DNA sequences to immobilized oligoprobes under equilibrium conditions

A new set of modified oligonucleotides based on those described above was designed. Three biotinylated probes containing an 8-mer complementary sequence with a spacer tri-T in the 5'-end were constructed. Two 19-mer targets, one "wild-type" and one "mutant" with C changed to T, were also constructed.

20

25

30

35

15

5

10

5 - CCTCAGCATCTTATCCGAG	BP68	"wt"
5′	BP69	"mutC>T"
GTAGAATAttt-B-5	BP63	
AGTCGTAGttt-B-5	BP64	
GAATAGGCttt-B-5	BP66.	

BP68 and 69 correspond to BP44 and 45, except that they are not biotinylated and the extra tri-T ("ttt") of either end has been deleted. BP63, 64 and 66 correspond to BP52, 49 and 55, respectively.

BP63, 64 and 66 were captured in Fc1-3 (554, 782 and 651 RU, respectively) and BP68 and 69 were passed over the flow cells in a serial mode. The concentrations used were 63 nM - 64  $\mu$ M. The results are shown in the sensorgrams in Fig. 8 (BP68) and Fig. 9 (BP69), where the binding of the two targets to the three probes are compared (blank surface sensorgram is subtracted). As seen in the Figures, the wttarget binds to all probes, but with different affinities.

20

25

30

35

BP64 binds best, then BP63 and finally BP66 with the lowest affinity. The mutant target shows reduced binding to all three probes, with no binding at all to BP63. This is the probe with the central mismatch. Thus, the 5´- and 3´-end mismatched probes still bind the target, but with about half the  $R_{eq}$ -response of the wt target. However, the binding deviates sligthly from that obtained in the straight mode; the on-rate is slightly lower and the binding looks more stable. At the lower concentrations, no steady-state is attained, but a slow binding is observed. The  $R_{eq}$ -responses were used to estimate the affinities via BIAeval<sup>TM</sup>. In Table 1 below, the values obtained are demonstrated.

15 Table 1

	Targe	et	Probe	Mismatch	K <u>a (m-1)</u>
	BP68	(wt)	BP63	no	$1.5 \times 10^{5}$
	BP68	(wt)	BP64	no	$3.2 \times 10^{5}$
)	BP68	(wt)	BP66	no	$3.1 \times 10^5$
	BP69	(mutant)	BP63	internal	-
	BP69	(mutant)	BP64	5´-end	$0.5 \times 10^{5}$
	BP69	(mutant)	BP66	3'-end	$0.3 \times 10^{5}$

Thus, also the reversed mode shows a clear discrepancy between end mismatch and internal mismatch. Also in this experiment, 5'-end mismatch has less effect than 3'- dito with respect to affinity.

As demonstrated above, an analysis of oligonucleotide hybridisation can be performed by measuring annealing under equilibrium conditions. The measurements are performed near or above the Tm-values of the 8-mer probes, which allows a very sensitive analysis. This is a major advantage compared to many other methods, where stringency conditions must be very carefully selected if precision should not be sacrificed. The analysis is fast, less than 3 minutes contact time, about 5 min/cycle, and regeneration is not

10

15

20

25

30

35

needed. Fully matched 8-mer probes bind with  $\mu M$ -order affinity (25 °C, 0.5 M salt).

#### EXAMPLE 3

A series of oligoprobes BP47-BP51, BP35 and BP52-56 were introduced into BIAcore 2000 with immobilized target wild-type (wt) BP44 and mutant variant BP45 on different surfaces passed in series by the liquid flow. The experiment was run at 30°C at 32  $\mu$ M concentration of the different oligoprobes diluted in buffer. The flow rate was 15  $\mu$ l/min and the injected sample volume was 30  $\mu$ l. The results are shown in Fig. 10.

As seen in the Figure, the dilution gave rise to a dilution effect during the sample introduction and a rapid decrease in response signal during the sample pulse. The diamond (\*) labelled curve (thick line) shows the interaction with target BP45 mutant and the thin line shows the interaction with wt BP44. During the washing phase between the introduction of the respective oligoprobes BP47-51, a dissociation signal can be seen in the wt response curve, whereas the dissociation for the other oligoprobes was rapid at the temperature used and cannot be resolved from the change in buffer composition. As is clearly demonstrated in the Figure, the response levels for wt and mutant were different over the experiment where oligoprobes passes over the mutant position.

Fig. 11 shows a subtraction of the two sensorgrams in Fig. 10 from each other, demonstrating that the difference in response under the annealing conditions gave rise to an increase in signal at the position of a mutation in the mini-sequencing type procedure performed. The diagram shows that the mutation starts with BP49 and ends with BP55 where the difference in signal is well separated from the baseline. (The spikes in the diagram are due to the short time differences for the sample to pass over the two different surfaces with wt and mutant target DNA, respectively.)

10

## EXAMPLE 4

The response at equilibrium for the interaction of oligoprobe BP 61 in full match with immobilized target BP 46 was studied at different concentrations and different temperatures ranging from 5 to 35°C. The experiment was run in buffer 2xSSC, a citrate buffer with 0.3 M NaCl, pH about 7. The flow rate was 15  $\mu$ l/min and the injected sample volume was 45  $\mu$ l. The results are shown in Fig. 12.

The affinity was calculated in the same way as in Example 1, and Table 2 below gives the values for both the obtained equilibrium association affinity constant  $(K_A)$  and the corresponding dissociation rate constant  $(k_{diss})$  for the studied temperatures.

15 <u>Table 2</u>

Temp. (°C)	KA	k <sub>diss</sub>
5	$1.51 \times 10^6$	$2.49 \times 10^{-3}$
15	$9.31 \times 10^5$	0.02
20	$6.74 \times 10^5$	0.11
22	$5.13 \times 10^5$	0.14
25	$2.83 \times 10^{5}$	>0.2
28	$2.01 \times 10^5$	>0.2
35	$3.74 \times 10^4$	>0.2

25

#### CLAIMS

- A method of analysing nucleic acid sequences, which method comprises measuring by surface sensitive detection technique the binding interaction between a first nucleic acid sequence and a second nucleic acid sequence, one of the first and second nucleic acid sequences being immobilized to a solid phase surface, to determine the affinity or an affinity related parameter for the binding reaction as indicative of the extent of complementarity 10 between the first and second nucleic acid sequences, characterized in that the measurement of the binding interaction is performed at annealing conditions adjusted such that the dissociation rate constant for the binding interaction corresponding to full complementarity between 15 the first and second nucleic acid sequences is greater than about  $10^{-3}$  per second, thereby permitting equilibrium for the interaction to be rapidly attained.
- 20 2. The method according to claim 1, characterized in that said measurement is performed at equilibrium.
  - 3. The method according to claim 1 or 2, characterized in that the dissociation rate constant is greater than about  $10^{-2}$  per second, preferably greater than about  $10^{-1}$  per second.
- The method according to claim 1, 2 or 3, characterized in that the first nucleic acid sequence is at least one
   oligonucleotide probe and the second nucleic acid sequence is at least one target nucleic acid sequence to be sequence analysed.
- 5. The method according to any one of claims 1 to 4,
  35 characterized in that the first nucleic acid and second nucleic acid sequences independently are single- or double-stranded DNA or RNA, or single-stranded DNA or RNA

25

30

35

complexed with a different molecule, such as a modified nucleic acid, a peptide or PNA.

- 6. The method according to any one of claims 1 to 5, characterized in that said adjustment of the annealing conditions comprises adjusting the temperature and/or the reaction medium.
- 7. The method according to any one of claims 4 to 6,10 characterized in that said oligonucleotide probe or probes are bound to the solid phase surface.
- 8. The method according to claim 7, characterized in that the method comprises the additional step of determining the dissociation constant for the binding reaction to determine therefrom the possible presence of repeated sequences in the target nucleic acid sequence.
- The method according to any one of claims 4 to 6,
   characterized in that the target nucleic acid sequence is bound to the solid phase surface.
  - 10. The method according to claim 9, characterized in that the method comprises scanning the target nucleic acid sequence for a mutation or mutations with a first set of oligonucleotide probes to detect a mutated part or parts of the target sequence, and then testing a detected mutated part or parts of the target sequence with a second set of oligonucleotides to determine the position of the mutation or mutations and optionally the corresponding base change.
  - 11. The method according to any one of claims 1 to 10, characterized in that said first or second nucleic acid sequences are immobilized in an array at defined positions on the solid phase surface.
  - 12. The method according to any one of claims 1 to 11, characterized in that the method comprises the additional

į

WO 97/04129 PCT/SE96/00949

23


step of determining the concentration of active first or second nucleic acid sequence at diffusion rate limited conditions.


- 5 13. The method according to any one of claims 1 to 12, characterized in that said surface sensitive detection technique is based on evanescent wave sensing.
- 14. The method according to any one of claims 1 to 13,10 characterized in that the measurement is performed in a flow cell.

15


20


- 15. Use of the method according to any one of claims 1 to 14 for the detection of point mutations.
- 16. Use of the method according to any one of claims 1 to 14 for sequencing of known or unknown nucleic acid sequences.





3/10













FIG. 5

















### INTERNATIONAL SEARCH REPORT

International application No. PCT/SE 96/00949

## A. CLASSIFICATION OF SUBJECT MATTER IPC6: C12Q 1/68 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC6: C12Q, G01N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE,DK,FI,NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EDOC, WPI, MEDLINE, BIOSIS, DBA, SCISEARCH C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. WO 9325909 A1 (PHARMACIA BIOSENSOR AB), 1-15 23 December 1993 (23.12.93) A WO 9306241 A1 (THE SECRETARY OF STATE FOR DEFENCE 1-15 IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND), 1 April 1993 (01.04.93), page 7, line 29 - line 33 A Microchemical Journal, Volume 47, 1993, 1-15 Sheila J. Wood, "DNA-DNA Hybridization in Real Time Using BIAcore page 330 - page 337 | χ | See patent family annex. X Further documents are listed in the continuation of Box C. Special categories of cited documents: later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document defining the general state of the art which is not considered to be of particular relevance document of particular relevance: the claimed invention cannot be considered movel or cannot be considered to involve an inventive step when the document is taken alone "E" erlier document but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination document referring to an oral disclosure, use, exhibition or other being obvious to a person skilled in the art document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 1 8 -10- 1996 15 October 1996 Name and mailing address of the ISA/ Authorized offices Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Patrick Andersson Telephone No. +46 8 782 25 00 Facsimile No. +46 8 666 02 86

## INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 96/00949

C (Continu	lation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No	
A	Biosensors & Bioelectronics, Volume 7, 1992, C.R. Graham et al, "Gene probe assays on a fibre-optic evanescent wave biosensor", page 487 - page 493, see page 489, column 2, line 7 - line 10 and line 44 - line 48	1-15	
	<b>~~</b>		
A	Nature, Volume 361, January 1993, Magnus Malmqvist, "Biospecific interaction analysis using biosensor technology" page 186	1-15	
	<del></del>		
A	Biosensors & Bioelectronics, Volume 9, 1994, Ingemar Lundström, "Real-time biospecific interaction analysis", page 725 - page 736, table I	1-15	
	<del></del>		
٨	WO 9013666 A1 (AMERSHAM INTERNATIONAL PLC), 15 November 1990 (15.11.90)	16	
l	<del>-</del> -		
	A/210 (continuation of second sheet) (July 1992)		

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

01/10/96 PCT/SE 96/00949

Patent document cited in search report		Publication date		t family mber(s)	Publication date
WO-A1-	9325909	23/12/93	EP-A-	0645015	29/03/95
			JP-T-	7507865 	31/08/95
WO-A1-	9306241	01/04/93	AU-B-	665369	04/01/96
	•		AU-A-	2564192	27/04/93
		•	BG-A-	98660	31/03/95
			CA-A-	2116239	01/04/93
			CZ-A-	9400521	13/07/94
			EP-A-	0604506	06/07/94
			FI-A-	941220	15/03/94
			GB-A.B-	2274710	03/08/94
			GB-D-	9402823	00/00/00
			HU-A-	68771	28/07/95
			HU-D-	9400770	00/00/00
			JP-T-	6510670	01/12/94
			NO-A-	940901	16/05/94
			SK-A-	30694	06/07/94
WO-A1-	9013666	15/11/90	CA-A-	<b>20455</b> 05	12/11/90
			EP-A-	0471732	26/02/92
			JP-T-	4505251	17/09/92